Pandemic, Vaccination and Risk Groups: A Multi-Centered Study
The outcomes of Sars-CoV-2 pandemic are still seen worldwide. Although the virus lost its severity, the pathogen continues to be a threat for risk groups. It is evident that the first and only precaution is vaccination. Immunosuppressant patients, however, might have altered vaccine responses, and they are more prone to be infected by the virus. KUISCID researchers have completed their study “BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac” and published it in Viruses Journal.
